NovelMed Therapeutics

NovelMed Therapeutics is a privately held, pre-revenue biotech founded in 2012, focused on developing first-in-class and best-in-class antibody therapies that selectively inhibit the complement Alternative Pathway. Its lead asset, Ruxoprubart (NM8074), has generated promising Phase II proof-of-concept data in PNH and holds Orphan Drug Designation, positioning it to address a significant share of the rare disease market. The company's highly differentiated mechanism aims for a favorable safety profile and supports a broad pipeline targeting over 20 indications across ophthalmology, nephrology, hematology, and neurology. NovelMed is actively seeking partnerships and investment to advance its clinical programs and capitalize on an addressable market estimated at over $400 billion.

Platform for developing monoclonal antibodies that selectively inhibit the complement system's Alternative Pathway while sparing the Classical and Lectin pathways, aiming for targeted efficacy and improved safety.

NovelMed competes in the complement inhibition market against established C5 inhibitors (Alexion/AstraZeneca's Soliris/Ultomiris) and a recently approved oral factor B inhibitor (Novartis's Fabhalta). In Geographic Atrophy, it would compete with approved AP inhibitors (Apellis's Syfovre, Iveric Bio/Astellas's Izervay). Its differentiation hinges on its selective AP blockade and potential safety advantages.